SignalPath was founded in 2014 with a similar goal to change the way that clinical research is conducted, and a specific focus on building state-of-the-art software to improve efficiency for clinical research sites. In addition, the Baseline community now numbers more than 500,000 individuals who are interested in participating in clinical research and automatically matched with research opportunities that meet their interests and profiles. The Baseline platform enables better and faster clinical trial execution, improved data aggregation and analysis, flexible study options designed for decentralized and hybrid trials, and the ability to capture real-world data, such as that generated by novel sensors and biomarkers. The acquisition will strengthen and expand Verily's existing clinical trial system and evidence generation platform, known as Baseline. Together, we will advance digital solutions to improve ease, quality, efficiency and speed in the current clinical trial paradigm." "It's our goal to modernize the way clinical trials are conducted for patients, researchers and sponsors alike. "Joining forces helps to accelerate and scale our shared vision, increase efficiency and lower costs in clinical trials, empower clinical research sites with world class technology, and ultimately bring medicines to patients faster," said Amy Abernethy, MD, PhD, President of Clinical Studies Platforms at Verily. SOUTH SAN FRANCISCO AND RALEIGH, NC - AUGVerily, an Alphabet company, and SignalPath today announced that they have entered into an agreement in which Verily will acquire SignalPath, a privately held company based in Raleigh that has developed the SignalPath platform, a clinical trial management system (CTMS) that improves the ease, quality and efficiency of conducting clinical research at study sites. Acquisition Marks Alphabet Company's First Major Acquisition As Business Continues to Scale
0 kommentar(er)
